阳性益生菌通过抑制氨酸和Hippo-YAP通路来改善乙氨基诱导的肝毒性
Wenkang Gao1, Gang Wang2, Hang Yuan1
1Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Cell & bioscience
|March 7, 2025
概括
一种由Bifidobacterium Longum,Streptococcus thermophilus和Lactobacillus delbrueckii亚种bulgaricus (BSL) 组成的益生菌混合物通过恢复肠道细菌和抑制肝损伤途径来改善乙氨基诱导的肝损伤 (AILI). 氨酸通过激活河马路径来加剧AILI.
科学领域:
- 微生物学 微生物学
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
背景情况:
- 药物诱导性肝损伤 (DILI) 是一个重要的临床问题.
- 肠道微生物群失生症与DILI的发病有关.
- 调节肠道微生物群为DILI提供了一个治疗策略.
研究的目的:
- 为了研究益生菌混合物 (Bifidobacterium Longum,Streptococcus thermophilus,Lactobacillus delbrueckii亚种bulgaricus - BSL) 在减轻乙氨基诱导的肝损伤 (AILI) 的有效性.
- 在AILI中阐明BSL的潜在机制,重点关注肠道微生物群,肝炎和分子通路.
主要方法:
- 对DILI患者和健康对照群体肠道细菌群体的分析.
- 用BSL预先治疗小鼠,然后给予乙氨基.
- 鼠标样本的转录组,微生物组和代谢组测序.
- 在体外实验中评估白对乙氨基诱导的肝细胞损伤的影响.
主要成果:
- DILI患者和AILI小鼠表现出肠道细菌失生症 (克拉姆阳性细菌减少,克拉姆阴性细菌增加).
- 在BSL前期治疗缓解了AILI,减少了肝炎和亡,并恢复了肠道细菌平衡.
- BSL抑制了肝损伤的关键途径,包括Hippo和TGF-β信号传递.
- 在AILI小鼠中观察到含有分支链氨基酸 (BCAA) 的寡聚的增加,特别是白,与疾病严重程度和Hippo通路激活相关.
- 氨酸在体外和体内加剧了乙氨基诱导的肝细胞损伤,增加了氧化应激和恶化AILI.
结论:
- 通过调节肠道微生物群和抑制有害的肝脏通路,BSL显示出对AILI的保护作用.
- 肠道微生物群失生症,其特点是细菌组成的变化和氨酸等BCAA的增加,有助于AILI的发病.
- 准肠道微生物群和了解特定代谢物的作用,如白,对于开发DILI的新型治疗策略至关重要.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
334
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
334
Enzyme Inhibition
77.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.7K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
128
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
128
Phase II Reactions: Acetylation Reactions
157
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
157
Hepatic Drug Excretion: Enterohepatic Cycling
906
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
906
Enhanced Elimination of Poison
468
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
468


